Prescribe Reclast for a Once-Yearly Infusion of Proven Fracture Reduction and Yearlong Bisphosphonate Compliance
Sustained 3-year fracture risk reduction at key osteoporotic sites in the treatment of postmenopausal osteoporosis
70% relative risk reduction (ARR 7.6%) in vertebral fracture
41% relative risk reduction (ARR 1.1%) in hip fracture
25% relative risk reduction (ARR 2.7%) in nonvertebral fracture†
Significant increases in BMD
Common adverse events during the postinfusion period can be reduced with acetaminophen
The HORIZON Pivotal Fracture Trial (PFT) was a 3-year, multinational, randomized, double-blind, placebo-controlled study
7736 women with postmenopausal osteoporosis 65-89 years of age from 239 clinical centers in 27 countries received a 15 minute infusion of Reclast or placebo infusion once a year for 3 years
All women received 1000-1500 mg elemental calcium plus 400-1200 IU vitamin D supplementation per day
ARR=absolute risk reduction.
*Relative to placebo. †Nonvertebral fracture includes wrist, rib, arm, shoulder and hip fracture; excludes finger, toe and craniofacial fracture.
